Poolbeg Pharma plc (LON:POLB) CEO Jeremy Skillington joins DirectorsTalk Interviews to discuss the in-licencing of a novel, first-in-class RNA-based immunotherapy for respiratory virus infections.
Jeremy tells us more about this new deal, explains the terms, what being at a late pre-clinical stage means and explains the ultimate plan for this asset.
Poolbeg Pharma (LON: POLB) is a clinical stage infectious disease pharmaceutical company, with a clinical model which enables them to develop multiple products faster and more cost effectively than a traditional biotech model.